Gyre Therapeutics, Inc. (Nasdaq: GYRE) has officially closed its acquisition of Cullgen Inc., the company announced today, creating an integrated biopharmaceutical player with operations spanning…
uniQure (NASDAQ: QURE) shares experienced a dramatic 36 percent rally during Monday’s trading session. This significant movement followed reports of a high-profile leadership change at…
Halozyme Therapeutics, Inc. (NASDAQ: HALO) stands to benefit significantly from a recent regulatory milestone in the oncology sector. The company provides the essential ENHANZE drug…
March 06, 2026
Solid Biosciences Shares Surge 14% Following $240 Million Private Placement Announcement
Solid Biosciences Inc. (NASDAQ: SLDB) saw its shares climb 14% after revealing an oversubscribed $240 million private placement with institutional investors. The life sciences company,…
March 05, 2026
Anxiety Treatment Market Set for Explosive Growth, Poised to Hit $4.26 Billion by 2033
AI Enhanced Photo* The market for treatments targeting Generalized Anxiety Disorder (GAD) is entering a strong growth phase. Analysts expect the market to expand from…
February 27, 2026
Neurogene Shares Rally on FDA Breakthrough Therapy Designation for Rett Syndrome Therapy
Neurogene Inc. (NASDAQ: NGNE) shares climbed 30% in after-hours trading Thursday following a significant regulatory milestone. The U.S. Food and Drug Administration (FDA) granted Breakthrough…
February 23, 2026
Kraig Biocraft Laboratories Lands National Geographic Cover with Spider Silk Breakthrough
Kraig Biocraft Laboratories (OTCQB: KBLB), a global leader in spider silk technology, has captured the spotlight once again—this time on the cover of National Geographic’s…
February 20, 2026
Biotech Breakthrough: Revyve Outperforms Silver Standards in Study
Kane Biotech Inc. (OTCQB: KNBIF) recently announced the publication of pivotal clinical data regarding its Revyve Antimicrobial Wound Gel. The Journal of Wound Care published…
February 19, 2026
Moleculin Sacrifices Share Price for Clinical Runway
Moleculin Biotech, Inc. (NASDAQ: MBRX) experienced a sharp decline in its share price on the Nasdaq Capital Market following a strategic financing announcement. This significant…
February 10, 2026
BioCardia Completes FDA Pre-Submission for Helix Transendocardial Delivery Catheter
BioCardia, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapies for cardiovascular and pulmonary diseases, has taken an important regulatory step forward. Specifically, the…
January 26, 2026
Neurocrine Biosciences Advances Tardive Dyskinesia Pipeline with Phase 2 Study Initiation
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced a significant operational update today regarding its clinical pipeline. The company has officially initiated a Phase 2 clinical study…
January 20, 2026
Corvus Pharmaceuticals Soars to Eight-Year High on Promising Eczema Treatment Results
Biotech stock Corvus Pharmaceuticals (NASDAQ: CRVS) climbed to an eight-year high on Tuesday, fueled by encouraging results from its eczema treatment study. The company’s experimental…